X0508 4 2026-02-02 0 0001737287 Allogene Therapeutics, Inc. ALLO 0002057918 Beneski Benjamin Machinas 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Chief Technical Officer 0 Common Stock 2026-02-02 4 S 0 7549 1.73 D 210172 D Stock Option (Right to buy) 1.87 2026-02-02 4 A 0 373757 0 A 2036-02-02 Common Stock 373757 373757 D Restricted Stock Unit 2026-02-02 4 A 0 105720 0 A Common Stock 105720 105720 D Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. /s/Earl Douglas, Attorney-in-Fact 2026-02-04